Foghorn Therapeutics (FHTX)
(Real Time Quote from BATS)
$5.31 USD
-0.63 (-10.61%)
Updated May 10, 2024 01:18 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Foghorn Therapeutics Inc. [FHTX]
Reports for Purchase
Showing records 21 - 40 ( 75 total )
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials; Readying for FHD-286 Clinical Updates in 2Q:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Unlocking The BAF Opportunity Requires Further Patience; Reit. Buy and Lowering Our PT to $20 from $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Clinical Hold For FHD-609, Does Not Deter Our Positive BAF Targeting Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
FHD-609 Program on Pause; Reducing PT to $15 (from $20)
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Remain Bullish Ahead of FHD-286 Data in 1H23; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Q4 Financials; Line of Sight to Key Readouts in 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
SITC 2022 Conference Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Mechanistic rationale of FHD-286, Ahead of Initial 1H23 Data Leaves Us Bullish; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Foghorn Showcase Degraders Capability and New CBP Program at TPD Summit; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Glimpse into BRD9 Clinical Profile with PD Data; New Selective CBP Program
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Foghorn Therapeutics Inc.
Industry: Medical - Drugs
Reports of the Death of Synthetic Lethality are Grossly Exaggerated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R